扶正抗癌方对H_(22)荷瘤小鼠的抑瘤作用及其对IL-12和Survivin表达的影响  

Experimental study of fuzheng anti-carcinoma prescription on the anti-tumor effect and its impact on H22 tumor-bearing mice and their IL-12 and Survivin expression

作　　者：杨柳青[1] 张鸣[1] 陈建婷[1] 郝丽君[2] 陈光伟 于军[1] 余琦[4] 

机构地区：[1]西安医学院第二附属医院,西安710038 [2]安徽省马鞍山市中心医院,马鞍山243000 [3]陕西省中医学院,咸阳712000 [4]西安医学院,西安710021

出　　处：《陕西中医》2015年第5期634-636,共3页Shaanxi Journal of Traditional Chinese Medicine

基　　金：陕西省社会发展攻关课题(2014K11-01-01-07);陕西省教育厅科研计划项目(14JK1619;12JK1032);陕西省教育厅基础研究专项课题(14JK1616);西安医学院第二附属医院资助项目(12EFYFC06)

摘　　要：目的:通过实验研究扶正抗癌方对H22荷瘤小鼠的抑瘤作用及其对IL-12和Survivin表达的影响。方法:85只小鼠,随机抽取15只作为正常对照组(A),将剩余70只小鼠共同造模:在右腋皮下种植相同量的H22瘤株悬液,将造膜成功的小鼠随机纳入60只,采用每只右腋皮下接肝癌细胞悬液0.2mL再随机分成4组,于接种瘤细胞悬液24小时候开始给药。空白对照组(A):用生理盐水0.2mL/只/d;荷瘤对照组(B):用生理盐水0.2mL/只/d;连续给药14d,替加氟组(C):给予替加氟配置的液体灌胃0.2mL/只/d;扶正抗癌方组(D):浓度为1.89g/mL的中药煎剂灌胃,0.2mL/20g,1次/d,连续共14d;(扶正抗癌方组+替加氟组)联合用药组(E)组:扶正抗癌方浓缩浓度为3.78g/mL,0.1mL/20g,1次/d,替加氟浓缩浓度为30mg/mL的水溶液灌胃,0.1mL/20g,1次/d,联合灌胃。经口灌胃14d后,取瘤体称重,用免疫组化法检测各组IL-12和Survivin的表达。结果:联合用药组及、扶正抗癌方组、替加氟组各治疗组瘤组织Survivin表达显著下降,与荷瘤对照组比较具有非常显著性差异(P<0.01);IL-12检测结果示:联合用药组与扶正抗癌方组及替加氟组比较具有显著性差异(P<0.05),扶正抗癌方组与替加氟组比较无显著性差异(P>0.05);结论:扶正抗癌方具有抑制肝癌侵袭转移的作用,联合西药治疗可减毒增效,提高免疫功能,改善生存质量;其机制与抗肿瘤下调抑制细胞凋亡的Survivin同时促进IL-12的表达及抗肿瘤侵袭与转移有关。Objective：An experimental study fuzheng anti‐carcinoma prescription cancer H22 square inhibitory effect on tumor‐bearing mice and their IL‐12 and Survivin expression .Methods ：85 mice were randomly selected 15 as the normal control group （A） ,the remaining 70 mice were common modeling ：the same amount in the right axillary subcuta‐neous tumor strain H22 grown in suspension ,will make the film successful in mice included 60 randomized ,using each ac‐cess right axillary subcutaneous hepatoma cell suspension 0 .2mL then randomly divided into four groups ,the cell suspen‐sion was administered at the beginning of 24 childhood tumor inoculation .The control group （A）：saline 0 .2mL /only /day ;tumor‐bearing control group （B）：with saline 0 .2mL /only /day ;14 days continuous administration ,tegafur group （C）：give liquid tegafur configuration gavage 0 .2mL /only /day ;fuzheng anti‐carcinoma prescription group （D）：the concentration of 1 .89g /mL herbal decoction ,0 .2mL /20g ,1 times /day for a total of 14 days;（fuzheng anti‐carcino ma prescription group ＋ tegafur group） combination group （E） group：righting cancer square concentrate concentration 3 .78g /mL ,0 .1mL /20g ,1 times /day ,tegafurconcentrate concentration aqueous solution of 30mg /mL of gavage ,0 . 1mL /20g ,1 times /day ,the United gavage .By oral gavage for 14 days ,take the tumor weighed ,The expression of IL‐12 and Survivin detected by immunohistochemistry .Results ：The combined group and ,fuzheng anti‐carcinoma prescrip‐tion group ,tegafur group in each treatment group tumor Survivin expression was significantly decreased ,and the tumor‐bearing control group has a very significant difference （P 〈0 .01）;IL‐12 test results show ：combination therapy group and fuzheng anti‐carcinoma prescription group and tegafur party group has significant difference （P 〈0 .05） ,no signifi‐cant differences fuzheng anti‐carcinoma prescription group and tegafur group （P〉 0 .05）

关 键 词：肝肿瘤 实验性/中医药疗法 白细胞介素-12 @扶正抗癌方 

分 类 号：R735.7[医药卫生—肿瘤]